In diabetic patients, several prospective, randomized, and double-blind clinical trials for the dual PPAR (α and γ) agonist muraglitazar in comparison with the PPARγ agonist pioglitazone and placebo were associated with a higher incidence of major cardiovascular events as myocardial infarction or stroke [37]. The gene discussed is PPARG; the disease is myocardial infarction.